CD Bioparticles Unveils Gold Nanoparticles for Enhanced Flow Cytometry Applications

Published: 27 Nov 2024

Author: Precedence Research

Share :

CD Bioparticles announced its new Flow Cytometry Gold Nanoparticles, which will take cell analysis to a whole new level. Production of these nanoparticles will be aimed at providing a sensitive and flexible tool for instrument tuning with flow cytometry and accurate evaluation of particle or organism populations in solution. Flow cytometry is a popular technique for measuring and analyzing individual cells and particles and it requires precision and sensitivity. Gold nanoparticles, because of their strong light scattering properties, large surface area to volume ratio, and tunable surface chemistry, present a very unique opportunity for that end. When coupled with specific biomolecules like antibodies or aptamers, these nanoparticles can be precisely detected and analyzed from complex biological samples.

These space-age, high-tech nanoparticles have very versatile applications, with sizes ranging from 70 nm-400 nm, and high light scattering and absorption power from visible to near-infrared wavelengths. They are remarkably stable under vast thermal, mechanical, and chemical conditions, low in toxicity, and biocompatible, qualifying them as excellent candidates for biomedical research.

The DiagNano™ Gold Nanoparticles Trial Kit (Cat. No. BG-LargeKit-FCM) is offered by CD Bioparticles to aid researchers in enhancing their experiments. This trial kit contains gold nanoparticles in four sizes, which enables the control of flow cytometry parameters and interrogation of other particles and organisms in complex samples for accurately determined readouts. CD Bioparticles continues to lead in nanoparticle tool innovation, offering products for various research and industrial applications, including immunoassays, bioseparations, medical imaging, diagnostics, and drug and cancer therapies.

Flow Cytometry Market Size and Growth 2024 to 2033

The global flow cytometry market size accounted for USD 5.70 billion in 2024, accounted for USD 5.70 billion in 2024, and is anticipated to reach around USD 11.21 billion by 2033, expanding at a CAGR of 7.80% from 2024 to 2033.

Flow Cytometry Market Companies

• Danaher Corporation
• Becton
• Dickinson and Company
• Luminex Corporation
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Miltenyi Biotec
• Sysmex Corporation
• Stratedigm, Inc.
• Apogee Flow Systems Ltd.
• Sony Biotechnology, Inc.
• Thermo Fisher Scientific, Inc.

Revenue stats of major players in the market

Danaher Corporation Reports First Quarter 2024 Results

• Net earnings: $1.1 billion, $1.45 per diluted common share.
• Revenues: 2.5% year-over-year, $5.8 billion.
• Non-GAAP core revenue: 4.0% decrease.
• Operating cash flow: $1.7 billion, non-GAAP free cash flow: $1.4 billion.

Becton Dickinson's 2024 Revenue

• Current revenue: ₹1.671 Trillion.
• Revenue in 2023: ₹1.622 Trillion, an increase from ₹1.550 Trillion in 2022.
• Revenue is the total income generated from sales of goods or services.
• No expenses are subtracted from earnings.

Agilent Technologies, Inc. 2024 Revenue

• $6.51 Billion
•  Employs 18,000 globally.

Flow Cytometry Market Recent Developments

• In November 2024, BP Koirala Memorial Cancer Hospital in Chitwan launched a 'flow cytometry' service for blood cancer detection, requiring training from India and Kathmandu.   
• In September 2024, Biotium expanded its NucSpot® Nuclear Stains lineup, offering specificity and flexibility for nuclear counterstaining in life science research. These membrane-impermeant dyes target the nucleus with minimal fluorescence, enabling no-wash nuclear staining and versatile use in flow cytometry.
• In September 2024, Hamamatsu Photonics introduces the Cytoqube Light-Sheet Microplate Cytometer, a 3D cell screening instrument for rapid image analysis of multi-well cell culture plates. 
• In May 2024, Agilent Technologies introduces the NovoCyte Opteon Spectral Flow Cytometer, revolutionizing flow cytometry, enabling data acquisition, analysis, and reporting across various research, drug discovery, and therapy development domains. 
• In March 2024, Beckman Coulter Life Sciences launched the CytoFLEX nano Flow Cytometer, the first purpose-built nanoscale flow cytometer for research use, enabling 30-50% more data creation compared to current offerings. 
• In March 2024, Beckman Coulter Life Sciences received FDA clearance to distribute its DxFLEX Clinical Flow Cytometer in the US, expanding testing capabilities and offering up to 13-color options. 

We’ve prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344